在乙型肝炎病毒相关性肝硬化长时间使用替诺福韦和恩替卡

StephenW

Indian J Gastroenterol. 2015 Aug 6. [Epub ahead of print]
Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis.Goyal SK1, Dixit VK, Shukla SK, Ghosh J, Behera M, Tripathi M, Gupta N, Ranjan A, Jain AK.
Author information

• 1Department of Gastroenterology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, 221 005, India, [email protected].
  

AbstractBACKGROUND AND AIMS: Limited data is available from India on outcome and efficacy of tenofovir and entecavir in hepatitis B virus (HBV)-related cirrhosis when used for prolonged time. We report the long-term efficacy and outcome of these antiviral drugs in patients with chronic HBV infection, with compensated or decompensated cirrhosis.
METHODS: We retrospectively analyzed laboratory and clinical data of 400 HBV-related cirrhotic patients without access to liver transplantation, who were treated with tenofovir/entecavir therapy, from January 2007 to January 2014. Two hundred and ten (52.5 %) patients had at least one of the components of decompensation at baseline. Two hundred and twenty (55 %) and 180 (45 %) patients were initiated tenofovir and entecavir, respectively. Follow up period was 45 (12-68) months for tenofovir and 36 (11-60) months for entecavir.
RESULTS: At the end of 1 year, levels of HBV DNA <20 IU/mL were achieved in 91.8 % and 88.8 % of patients, and alanine aminotransferase normalized in 54.5 % and 55.5 % of patients who received tenofovir and entecavir, respectively. At the last visit, Child-Turcotte-Pugh scores improved among 29.5 % of patients who received tenofovir, 25 % of those who received entecavir, and remained stable in 61.9 % and 65 % patients, respectively, in both groups. The 5-year cumulative rate of liver decompensation, hepatocellular carcinoma, and cirrhosis-related complications were 3.1 %, 1.9 %, and 2.1 % with an annual incidence of 0.8 %, 0.3 %, and 0.5 % per person-year, respectively.
CONCLUSION: Tenofovir and entecavir were effective and potent drugs for prolonged treatment of HBV cirrhosis and improved the overall clinical course.

StephenW

印度ĴGastroenterol。 2015年6月[EPUB的提前打印]
在乙型肝炎病毒相关性肝硬化长时间使用替诺福韦和恩替卡韦。
戈亚尔SK1，迪克西特VK，SK舒克拉，戈什Ĵ，Behera男，特里帕蒂男，古普塔N，兰詹A，耆那教AK。
作者信息

    消化内科教研室，医学科学研究所，贝拿勒斯印度教大学瓦拉纳西，221 005，印度，[email protected]的。

抽象
背景和目的：

有限的数据可从印度的成果和替诺福韦和恩替卡韦乙肝病毒（HBV）相关肝硬化疗效用于延长时间。我们报告的长期疗效，这些抗病毒药物和结果慢性HBV感染，代偿或失代偿性肝硬化。
方法：

我们回顾性分析实验室和400乙肝相关肝硬化患者的临床资料，无法获得肝移植，是谁替诺福韦/恩替卡韦治疗治疗，2007年1月至2014年1月二百一十（52.5％）患者中至少有一个失代偿的部件在基准。两百二十种（55％）和180（45％）患者发起替诺福韦和恩替卡韦，分别。随访期为45（12-68）个月的替诺福韦和36（11-60）个月的恩替卡韦。
结果：

1年结束时，HBV DNA的水平<20 IU / mL的在91.8％的患者88.8％实现，谷丙转氨酶正常化在54.5％和谁分别接收替诺福韦和恩替卡韦，患者55.5％。在上次访问，儿童特科特-Pugh评分之中谁收到替诺福韦，谁收到的恩替卡韦25％，并保持稳定在61.9％和65％的患者，分别在两组患者的29.5％提高了。肝功能失代偿，肝细胞癌，和肝硬化相关的并发症的5年累积率分别为3.1％，1.9％，及2.1％与0.8％，0.3％和0.5％每人年，每年的发病率。
结论：

替诺福韦和恩替卡韦是有效的和有效的药物长期治疗乙肝肝硬化并提高了整个临床过程。

咬牙硬挺

感谢分享